medigraphic.com
ISSN 1561-3070 (Electronic)

2021, Number 3

<< Back Next >>

Rev Cub Oftal 2021; 34 (3)

Non-surgical, surgical and reconstructive treatment of basal cell eyelid carcinoma

Batista PM, Arzuaga HE, González PS, Pérez PES

Language: Spanish
References: 30
Page: 1-24
PDF size: 509.66 Kb.


ABSTRACT

A bibliographic search was conducted about basal eyelid carcinoma with the purpose of describing the current context of surgical, non-surgical and reconstructive treatment. Current management of this condition includes many treatment options aimed at removing the tumor with the least possible functional and esthetic sequels. Among them are the following: topical medication (imiquimod, interferons, vismodegib, sonidegib), minimally invasive procedures (photodynamic therapy), ablative therapy (curettage, electrocauterization, cryosurgery) and highly specialized procedures (conventional surgical resection, radiotherapy or Mohs surgery). Surgical planning should consider the previous treatment, the histological subtype, and the site and size of the lesion. These factors have been shown to affect cure rates. Based on these elements, an algorithm was developed for the treatment of basal cell carcinoma which may be useful in selecting the surgical technique and safety margins, particularly in settings where micrographic surgery is not widely available.


REFERENCES

  1. Pfeiffer MJ, Pfeiffer N, Valor C. Descriptive study on basal cell eyelid carcinoma. Arch Soc Esp Oftalmol. 2015;90(9):426-31. DOI: https://doi.org/10.1016/j.oftale.2015.10.007

  2. Jacobs G, Rippey J, Altini M. Prediction of aggressive behavior in Basal Cell Carcinoma. Cancer.1982 [acceso: 15/06/2021];49:533-37. Disponible en: https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19820201)49

  3. Tzoutzos K, Batistatou A, Kitsos G, Liasko R, Stefanou D. Retrospective clinicopathological study of 129 cancerous and 18 precancerous lesions of the eyelids in North-Western Greece. Int Ophthalmol.2017;37(1):203-8. DOI: https://doi.org/10.1007/s10792-016-0258-8

  4. Olmos M, Portilla N, Castro C. Tratamiento quirúrgico y reconstrucción del cáncer periorbitario. Rev Asoc Colomb Dermatol. 2013 [acceso: 15/06/2021];21(3):226-38. Disponible en: https://revista.asocolderma.org.co.index.php.asocolderma.article/view/257

  5. Bichakjian CK, Olencki T, Aasi SZ, Alam M, Andersen JS, Berg D, Engh A. Basal cell skin cancer. NCCN Clinical practice guidelines in oncology. J Nat Compreh Canc Netw. 2016 [acceso: 15/06/2021];14(5):574-59. Disponible en: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp

  6. Barbosa F, Ferron C, Perez G. Surgical treatment of basal cell carcinoma: an algorithm based on the literature. An Bras Dermatol. 2015;90(3):377-83. doi: https://doi.org/10.1590/abd1806-4841.20153304

  7. Iljin A, Zielinski T, Antoszewski B, Sporny S. Clinicopathological analysis of recurrent basal cell carcinoma of the eyelid. Postepy Dermatol Alergol. 2016;33(1):42-46. DOI: https://doi.org/10.5114/pdia.2015.48039

  8. Lewin JM, Carucci JA. Advances in the management of basal cell carcinoma. Prim Rep. 2015;7:53. DOI: https://doi.org/10.12703/P7-53

  9. Fahradyan A, Howell AC, Wolfswinkel EM, et al. Updates on the Management of Non-Melanoma Skin Cancer (NMSC). Healthc Basel Switz. 2017;5:(4):82. DOI: https://doi.org/10.3390/healthcare5040082

  10. Van Loo E, Mosterd K, Krekels M, Roozeboom H, Ostertag J, Dirksen C, et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. Europ J Canc. 2014;50(17):3011-20. DOI: https://doi.org/10.1016/j.ejca.2014.08.018

  11. Van Kester MS, Goeman JJ, Genders RE. Tissue-sparing properties of Mohs micrographic surgery for infiltrative basal cell carcinoma. J Am Acad Dermatol 2019;80:1700-3. DOI: https://doi.org/10.1016/j.jaad.2019.01.057

  12. Shi Y, Jia R, Fan X. Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment. OncoTarg Ther. 2017;10:2483-89. DOI: https://doi.org/10.2147/OTT.S130371

  13. Karabulut GO, Kaynak P, Ozturker C, et al. Imiquimod 5 % cream for the treatment of large nodular basal cell carcinoma at the medial canthal area. Ind J Ophthalmol. 2017;65:48-51. DOI: https://doi.org/10.4103/ijo.IJO_958_16

  14. De Macedo EM, Carneiro RC, de Lima PP, Silva BG, Matayoshi S. Imiquimod cream efficacy in the treatment of periocular nodular basal cell carcinoma: a non-randomized trial. BMC Ophthalmol. 2015;15:35. DOI: https://doi.org/10.1186/s12886-015-0024-0

  15. Good LM, Miller MD, High WA. Intralesional agents in the management of cutaneous malignancy: a review. J Am Acad Dermatol. 2011;64(2):413-22. DOI: https://doi.org/10.1016/j.jaad.2009.12.013

  16. Fernández M, Bello I, Duncan Y. Treatment of Basal Cell Carcinoma with Interferons Alpha-2b and Gamma in Primary Care. MED Rev. 2018;20(1):11-17. DOI: https://doi.org/10.37757/MR2018.V20.N1.4

  17. Bello I, García Y, Valenzuela C, Bello C, Vázquez D, López P. Development of a new formulation of interferons (HEBERPAG) for BCC treatment. Canc Res Ther. 2013;1(10):235-43. DOI: https://doi.org/10.14312/2052-4994.2013-36

  18. Jiménez Y, Vega C, Vila D, Fernández G, Arias V, Bello I. Uso de HeberPAG en carcinoma basocelular periocular. Rev Cubana Oftalmol. 2014 [acceso: 15/06/2021];27(3):482-89. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21762014000300014

  19. García Y, Anasagasti L, Valenzuela C, Navarro M, Maribeth S, Acosta D, et al. Retrospective Study of Periocular Non Melanoma Skin Cancer Treated with the Combination of IFN alpha2b and Gamma (HeberPAG). J Clin Exp Ophthalmol. 2015;6:5. DOI: https://doi.org/10.4172/2155-9570.1000478

  20. Centro de Ingeniería Genética y Biotecnología. Informe Periódico de Seguridad del HeberPAG. CIGB; 2013.

  21. Velter C. Place de la radiothérapie dans le traitement du carcinome basocellulaire. Ann Dermatol Vénéréologie. 2018;145:VS30-5. DOI: https://doi.org/10.1016/S0151-9638(18)31256-0

  22. Erdem GU, Sendur MA, Ozdemir NY, Yazici O, Zengin N. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma. Curr Med Res Opin. 2015;31(4):743-56. DOI: https://doi.org/10.1185/03007995.2015.1018988

  23. Demirci H, Worden F, Nelson CC, Elner VM, Kahana A. Efficacy of vismodegib (Erivedge) for basal cell carcinoma involving the orbit and periocular area. Ophthalmol Plast Reconstr Surg. 2015;31(6):463-66. DOI: https://doi.org/10.1097/IOP.0000000000000388

  24. Sekulic A, Migden MR, Basset-Seguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal. BMC Canc. 2017;17:332. DOI: https://doi.org/10.1186/s12885-017-3286-5

  25. Basset N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): A pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015;16(6):729-36. DOI: https://doi.org/10.1016/S1470-2045(15)70198-1

  26. Dummer R, Guminski A, Gutzmer R, et al. The 12-month analysis from basal cell carcinoma outcomes with LDE225 treatment (BOLT): a phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016;75(1):113-25. DOI: https://doi.org/10.1016/j.jaad.2016.02.1226

  27. Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716-28. DOI: https://doi.org/10.1016/S1470-2045(15)70100-2

  28. Danial C, Sarin KY, Oro AE, Chang AL. An investigator initiated open label trial of sonidegib in advanced basal cell carcinoma patients resistant to vismodegib. Clin Cancer Res. 2016;22(6):1325-9. DOI: https://doi.org/10.1158/1078-0432.CCR-15-1588

  29. González JL, Santos D, Abreu FA, Melgares MA, Valdivia YT. Aplicación de técnicas reconstructivas en el manejo de los pacientes con tumores malignos del párpado inferior. Rev Cub Oftalmol. 2016 [acceso: 15/06/2021];29(2):229-40. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21762016000200005

  30. Hernández Y, Sánchez Y, Estrada B. Colgajos o injertos cutáneos para la corrección de defectos palpebrales de gran tamaño. Rev Cubana Oftalmol. 2018 [acceso: 15/06/2021];31(4). Disponible en: http://www.revoftalmologia.sld.cu/index.php/oftalmologia/article/view/615/523




2020     |     www.medigraphic.com